A carregar...
Alzheimer's disease drug development and the problem of the blood-brain barrier
Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small molecule drugs, and ∼100% of all large molecule drugs, do not cross the BBB. Despite the fact that the vast majority of AD drug candidates do not cross the BBB, the...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2756824/ https://ncbi.nlm.nih.gov/pubmed/19751922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2009.06.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|